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The 2-oxoglutarate dehydrogenase (OGDH) complex is an important control point in 
vertebrate mitochondrial oxidative metabolism, including in the citrate cycle and catabolism 
of alternative fuels including glutamine.  It is subject to allosteric regulation by NADH and 
ATP/ADP ratio, and by Ca2+ through binding to the E1 subunit.   The latter involves a unique 
Ca2+ binding site which includes D114ADLD (site 1).  Here, we describe three splice variants of 
E1 in which either the exon expressing this site is replaced with another exon (Loss of site1, 
LS1), or an additional exon is expressed leading to the insertion of 15 amino acids just 
downstream of site1 (Insert), or both changes occur together (LS1/Insert). We show that all 
three variants are essentially Ca2+-insensitive.  Comparison of massive parallel sequence 
(RNA-Seq) databases demonstrates predominant expression of the Ca2+-sensitive archetype 
form in heart and skeletal muscle, but substantial expression of the Ca2+-insensitive variants 
in brain, pancreatic islets and other tissues. Detailed proteomic and activity studies 
comparing OGDH complexes from rat heart and brain confirmed the substantial difference 
in expression between these tissues.  The evolution of OGDH variants was explored using 
bioinformatics, and this indicated that Ca2+-sensitivity arose with the emergence of 
chordates.  In all species examined, this was associated with the co-emergence of Ca2+-
insensitive variants suggesting a retained requirement for the latter in some settings.  
Tissue-specific expression of OGDH splice variants may thus provide a mechanism that tunes 




2-Oxoglutarate dehydrogenase plays a central role in the regulation of intramitochondrial 
energy metabolism.  We show that three Ca2+-insensitive splice variants are expressed to 
varying degrees in different tissues allowing potential important tuning to the metabolic 





Ca2+-insensitive splice variants of OGDH complex 
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Abbreviations :-  DHTKD1, dehydrogenase E1 and transketolase domain-containing 1;  DTT, 
dithiothreitol; HEDTA, N-hydroxyethylethylenediamine-triacetic acid;  LS1, Loss of site 1;  
MCU, mitochondrial Ca2+-uniporter;  OGDH, 2-oxoglutarate dehydrogenase; OGDHL, OGDH-
like, TEV, tobacco etch virus; PSM, peptide spectral matches; RPKM, reads per kilobase of 
transcript per million mapped reads; TPP, thiamine pyrophosphate. 
 
INTRODUCTION 
The OGDH (2-oxoglutarate dehydrogenase) complex is important in the control of the 
citrate cycle and other intramitochondrial metabolic pathways including glutamine 
catabolism.  The complex from vertebrate sources comprises decarboxylase (E1), 
dihydrolipoate acetyl transferase (E2) and dihydrolipoate dehydrogenase (E3) subunits [1].  
It is exquisitely sensitive to regulation by the ATP/ADP ratio and by NADH, which provide an 
intrinsic response to changes in cellular energy status, and to Ca2+, which allows responses 
to external stimuli [2-7]. 
Recently we successfully expressed recombinant human OGDH E1 and developed an 
assay for its activity. This allowed us to show that all these important regulators act through 
binding to the E1 subunit [8], consistent with the stoichiometry of Ca2+ and ADP binding to 
the holo-complex (~3 sites / complex) [9].  In the case of Ca2+, the binding site was shown by 
a mutagenesis approach to involve the sequence D114ADLD (site 1), a site distinct from other 
previously described Ca2+ binding sites on other proteins [8].   OGDH E1 from vertebrate 
sources contain another similar site, E139SDLD (site2), close to site 1, but this second 
potential Ca2+-binding site appears to play no part in the regulation of activity by Ca2+ [8]. 
 As part of our exploration of proteins that might contain a Ca2+ binding site similar to 
the OGDH E1 binding sites, we carried out BLAST studies of EST databases.  These studies 
indicated that three splice variants of archetype OGDH E1 exist in man and other mammals 
(Figure 1a,b).  In the variant we refer to as ‘Loss of site 1 (LS1)’, the exon (exon 4) expressing 
site 1 in archetype OGDH E1 is replaced by another exon (exon  3) expressing a sequence 
lacking the DxDxD motif and would be expected to be Ca2+-insensitive.  There is another 
splice variant involving exon 5 we call ‘Insert’ which gives an insertion of 15 additional 
amino acids between site 1 and site 2.  This insertion can apparently exist with both 
archetype and LS1 variants giving a total of four sequence alternatives in the site1/site2 
region of OGDH E1.   (These variants in human and other species are often referred to as 
isoforms 1-4 in the various annotated databases but the numbering is very inconsistent and 
not used in this article). 
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The aims of the present studies were first to establish the Ca2+-sensitivity and other 
regulatory properties of these splice variants.  We then explore the extent to which the 
splice variants are expressed across mammalian tissues using RNA-Seq and proteomic 
approaches and describe studies comparing the Ca2+-sensitivity of the OGDH complex from 
heart and brain.  These tissues were selected as they show very different levels of 
expression of the various splice variants. 
 
MATERIALS AND METHODS 
Materials 
[1-14C] 2-oxoglutarate sodium salt was obtained from Hartmann Analytic.  Other materials 
were from Sigma-Aldrich or Fisher Scientific.    
Expression and purification of human OGDH E1 and splice variant forms; study of their 
kinetic properties 
DNAs encoding human OGDH E1 and its splice variants (lacking the mitochondrial 
propeptide but containing a tobacco etch virus protease cleavable polyhistidine tag) housed 
in pJexpress 404 vectors and optimized for expression in E.coli were purchased from DNA 
2.0.  Protein expression and purification was as previously described [8]. The OGDH E1 
preparations (0.2-0.4 mg of protein/ml) were divided into small samples and stored at -
80oC.  Repeated freezing and thawing was avoided as it resulted in some loss of activity.  
The polyhistidine tag was not cleaved since our previous studies showed that the presence 
of the tag had no significant effect on the kinetic properties of expressed human OGDH E1 
[8]. 
Activity of expressed OGDH E1 variants was assayed by following the 
decarboxylation of [1-14C] 2-oxoglutarate in the presence of glyoxylate at 30oC, usually for 
30 min [8].  Final assay conditions used throughout were:-  50 mM Mops (pH 7.2) containing 
75 mM KCl, 0.2 mM EGTA, 1 mM HEDTA (N-hydroxyethylethylenediaminetri-acetic acid), 1 
mM DTT, 1µg/ml oligomycin,  1µg/ml rotenone, 1 mM TPP,  plus MgCl2 and CaCl2 to give 1 
mM Mg2+ and the appropriate concentration of Ca2+ together with the stated 
concentrations of adenine nucleotides, NADH and [1-14C] 2-oxoglutarate plus 5mM sodium 
glyoxalate.  The amounts of added MgCl2 and CaCl2 were determined using the computer 
program METLIG [10].  Maximum activity (Vmax) was measured at 0.33 mM Ca2+ and 2mM 2-
oxoglutarate in the absence of added adenine nucleotides and NADH. 
Extraction of OGDH complex from rat heart and brain mitochondria and study of its 
kinetic properties 
Mitochondria were prepared from whole hearts and brains of 250-350 g male Wistar rats 
following homogenization in sucrose isolation buffer (250 mM sucrose, 20 mM Tris–HCl, 
2 mM EGTA, pH 7.4) using a Polytron PT10 (heart) or a Dounce Potter homogenizer (brain) 
and purified by Percoll® density-gradient centrifugation.  The mitochondria were then 
sedimented by centrifugation at 10,000g for 5 min in an Eppendorf minicentrifuge and the 
pellet immediately frozen in liquid N2.  The mitochondria were then extracted by freezing 
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and thawing three times in 100 mM potassium phosphate buffer pH 7.2 containing 1mM 
DTT plus 30 ul.ml-1 foetal calf serum and 5 ug.ml-1 each of pepstatin A, aprotinin and 
leupeptin to prevent proteolysis.   
The extracts were then centrifuged at 10,000g for 5 min before assay of OGDH 
complex activity in the supernatant by following the production of NADH at 340 nm and 
300C.   Final conditions of the assay were the same as those used for the assay of OGDH E1 
activity described above but with the omission of sodium glyoxalate and the use of non-
radioactive 2-oxoglutarate together with the addition 1 mM NAD+ and 0.2 mM CoA.   See 
Armstrong et al. [8] for more details. 
Curve fitting and calculation of kinetic data 
Data were fitted to the equation given in figure legends using GraFit5. 
Determination of amounts of OGDH E1 
Concentrations of subunit E1 protein was determined by quantifying the intensity of the 110 
kDa band separated by SDS/PAGE (10% gel) using ImageJ [8]. 
RNA-Seq analysis 
Publicly-available RNA-Seq data for various tissues from adult C57BL/6 mice and embryonic 
stem cells (Bruce-4) (GEO Accession No GSE36026) were combined with RNA-Seq data for 
pancreatic islets and skeletal muscle (Accession Nos E-MTAB-2791, E-MTAB-3725 and 
GSM1020654).  Reads were assigned to the annotated mouse transcriptome (Ensembl 
assembly GRCm38) using the Sailfish algorithm [11].  cDNA sequences for the open reading 
frames of the four isoforms identified in this study were assembled and reads mapped to 
these, also using Sailfish. Expression levels were calculated as Reads Per Kilobase of 
transcript per million Mapped reads (RPKM) [12]. To study individual exon expression levels, 
the DEXSeq tool [13] was used on RNA-Seq data from brain cortex and heart samples (GEO 
Accession No GSE36026 and GSE36025).  A very large number of reads mapped to the last 
exon of Ogdh possibly due to mis-mapping or an overlapping transcript. To avoid this 
skewing of the normalisation of exon usage, the last exon was ignored in this analysis.  
Phylogenetic analysis 
Ogdh and related genes were identified in sequenced genomes of representative species 
using published gene annotations (ENSEMBL) and Blast searching. The full sequences of 
each of the major transcript variants were aligned using MUSCLE [14] and a phylogenetic 
tree constructed with the maximum likelihood model using MEGA (version 6.0)  software 
[15].    
Proteomic analysis 
Proteomic analyses were performed within the University of Bristol Proteomics Facility. 
Samples of expressed human OGDH splice variants were separated by SDS/PAGE 
(10% gel) and the 110 kDa band excised. 
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Samples of OGDH complex partially purified from rat brain and heart mitochondria:  
mitochondrial extracts were prepared as described above except that foetal calf serum was 
not added to the mitochondrial extraction buffer.   These samples were centrifuged at 
33,000 g for 20 min and the supernatants then centrifuged at 250,000 g for 60 min in a 
Beckman Optima TLX Ultracentrifuge using TLA55 and TLA100 heads respectively.  Proteins 
in the pellets were then separated by SDS/PAGE (10% gel) and the band corresponding to 
100-120 kDa excised. 
The excised bands were subjected to in-gel tryptic digestion and the resulting 
peptides fractionated using an Ultimate 3000 nanoHPLC system in line with either an LTQ-
Orbitrap Velos or Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific).  The raw 
files were processed with the Proteome Discoverer software v1.4 (Thermo Scientific) using 
the SEQUEST algorithm.  Searches were filtered to satisfy a false discovery rate of less than 
1%. 
RESULTS 
Comparison of the kinetic properties of the expressed human OGDH E1 splice variants 
with those of archetype OGDH E1 
All three splice variants were active when expressed as recombinant proteins and estimates 
were made of their specific activities compared to archetype E1.  Relative amounts of 
protein in archetype and variant E1 were measured from scans of the stained 110 kDa bands 
separated by SDS/PAGE.  Specific activities were then calculated using measurements of 
Vmax   determined at 2mM 2-oxoglutarate and 0.33 mM Ca2+ in the absence of added 
adenine nucleotides and NADH.  Values as % of archetype activity were LS1 85, Insert 78 and 
LS1/Insert 115 indicating that there were only small differences, if any, in the specific 
activities of the variants compared to archetype.  Since SDS/PAGE indicated that the E1 
bands accounted for much of the protein in the preparations, specific activities were also 
calculated based on the total protein in the preparations measured by the Pierce BCA assay 
using BSA as the standard.  The values obtained were (µmol/min per mg of protein):  WT, 
0.10;  LS1, 0.11;  Insert, 0.053;  LS1/Insert, 0.21.  Again the specific activities for the variants 
were similar to archetype but more variable than those based on gel scans, reflecting some 
differences in the purity of the preparations. 
 The effects of Ca2+, adenine nucleotides and NADH on the spice variants and 
archetype OGDH E1 were explored using surveys in which assays were carried out at 50 µM 
2-oxoglutarate under 12 different combinations of these regulators (Figure 2 and 
Supplementary Table S1).   Results with archetype OGDH E1 were very similar to those 
obtained in our previous study under the same conditions [8] and showed activation by Ca2+ 
and ADP and inhibition by ATP and NADH.  In particular, activation by 0.33mM Ca2+ was 
evident under all conditions.  In contrast, all three of the three splice variants exhibited 
little, if any, Ca2+ activation under any of the conditions studied while effects of adenine 
nucleotides and NADH were still clearly evident. 
 Confirmation of the extent of the loss of Ca2+ activation in the splice variants was 
obtained in a series of further studies in which the activity of archetype and splice variants 
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were compared at <10-5, 0.33 and 1 mM Ca2+ in the presence of 0.2 mM NADH and 50 µM 2-
oxoglutarate (Figure 3).  Archetype E1 exhibited a 13.4 fold increase in activity with 0.33 mM 
Ca2+ compared to <10-5 mM whereas the corresponding values for the variants were much 
smaller at 1.1, 2.2 and 1.4 fold for LS1, Insert and LS1/Insert respectively (similar effects 
were evident in Supplementary Table S1).   At 1 mM Ca2+, appreciable increases of 2.5 and 
4.8 fold respectively in activity of the variants LS1 and Insert were evident but only a 1.9 fold 
increase was apparent for the LS1/Insert; these were all considerably less than the 15.6 fold 
increase observed with archetype E1.    
 Studies into the effects of varying the NADH concentration at 50 µM 2-oxoglutarate 
in the absence of Ca2+ and adenine nucleotides revealed that the calculated Ki for NADH was 
increased by modest amounts in the splice variants, with LS1 showing the largest increase 
(Figure 4a).  Parallel studies on the effects of varying the ATP/ADP ratio at the same 2-
oxoglutarate concentration in the absence of Ca2+ and NADH revealed the ratio giving 50% 
inhibition was also slightly increased with the largest increases seen with Insert and 
LS1/Insert (Figure 4b).  Previous studies with archetype E1 in the absence of Ca2+ showed 
that NADH (0.2 mM) increased the Km for 2-oxoglutarate while markedly decreasing the Vmax 
[8].  All three splice variants also showed similar changes (Figure 5), though the Km for 2-
oxoglutarate in the absence of NADH was deceased.   
Expression of archetype and splice variants of OGDH E1 in a range of mouse tissues 
explored using RNA-Seq. 
The expression of the splice variants was investigated at the RNA level in mouse tissues 
using publicly-available RNA-Seq data (see Methods).  Initially, expression of the four 
different isoforms was estimated using the Sailfish tool (Figure 6a).  These data are also 
presented as the proportional expression of the four isoforms (Figure 6b).  Heart and 
skeletal muscle showed higher overall archetype expression than the other mouse tissues, 
and this was associated with very low expression of the three Ca2+ insensitive splice variants.  
In several other tissues there was a markedly different pattern of expression with the sum 
of expression of the three splice variants being comparable to that of archetype.  These 
included islet, cerebellum, cortex, thymus and spleen.  However, within this group 
appreciable differences in the relative expression of the three splice variants were evident.  
In islet and thymus tissue the LS1 variant was predominant, whereas in cerebellum, cortex 
and thymus similar expression of the three splice variants was observed.   In a third group of 
tissues, the sum of expression of the three splice variants was in the range of 10-30%.  These 
were ESC (embryonic stem cells), kidney, liver and lung.  Again, there were differences in the 
relative expression of the variants.  
Given the clearly contrasting pattern of expression at the RNA level, the data from 
heart and brain cortex were examined in more detail. Expression at the exon level was 
calculated using DEXSeq, which detects significantly differentially spliced exons while 
controlling for the overall expression level of the gene. The archetype and LS1 domains are 
encoded by a pair of exons (exons 4 and 3 respectively), one of which is included in each 
mRNA. The Insert domain is encoded by the subsequent exon (exon 5), and these three 
exons are highlighted in Figure 6c.  Much greater usage of both the LS1 and Insert exons is 
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apparent in the brain cortex compared to the heart.   Since DEXSeq measures the usage of 
each exon individually but not splicing between them, this tool does not indicate whether 
the Insert exon is associated with Archetype or LS1 exon usage. The Sailfish analysis (Figure 
6a,b), which does take account of splicing, indicates roughly equal quantities of Insert and 
LS1/Insert transcripts in cortex, although the ratio does vary across other tissues. 
 
Expression of archetype and splice variants of OGDH E1 in rat brain and heart explored 
using a proteomic approach. 
Figure 7 summarizes the peptides expected to be generated by the action of trypsin on the 
various splice variants of human OGDH E1.  Each of the forms has one unique peptide 
(peptides numbered 3 in archetype, 6 in LS1, 7 in Insert and 10 in LS1/Insert).  In addition, 
peptides 1 and 2 are restricted to archetype and Insert, peptides 4 and 5 to LS1 and 
LS1/Insert and peptides 8 and 9 to Insert and LS1/Insert.  Peptides a and b are shared by all 
four forms.  The figure also indicates two amino acid differences that occur in this region in 
rat and mouse compared to human. 
 Using either LTQ-Orbitrap Velos or the more sensitive Orbitrap Fusion Tribrid mass 
spectrometer, peptides 1,4,5 and 8 were never detected because their mass/charge ratios 
were less than the minimal detected ratio of 300 for both machines.  Peptides 6 and 10 
were also not observed in samples of human splice variant LS1 and LS1/Insert, possibly 
because of their high mass/charge ratio.  However, their calculated ratios based on an 
expected net charge of 2+ are 1830 and 1496 respectively, and these values are within the 
maximum detected ratio of 2000 for both machines.  Whatever the reason the lack of 
detection of these peptides from human sources that are unique to LS1 and LS1/Insert 
respectively may limit to some extent the application of proteomics in the determination of 
the expression of the four forms of OGDH E1 in tissue samples. 
 The number of peptide spectral matches (PSM) can be used as a measure of the 
amount of a particular peptide [16-18].  Figure 8a shows the values of PSM for the various 
relevant peptides with mass/charge ratios in the range 300-2000 which were detected in 
studies using the Orbitrap Fusion Tribrid mass spectrometer on samples of expressed 
human archetype and the three splice variants.  These have been expressed as percent of 
the total PSM observed for all the peptides in the relevant protein to correct for any 
variations in the amount of protein studied.  Results are also compared with the mean PSM 
observed in peptides a and b which are present in all four forms.  As expected peptides 2 
and 3 were observed in archetype OGDH E1 but not peptides 6,7,9 and 10.  None of these 
peptides were observed in LS1, whereas peptides 2,7 and 9 were found in Insert and 
peptide 9 in LS1/Insert.  This is the pattern of peptides predicted given the lack of detection 
of peptides 6 and 10.   
 When the same proteomic approach was applied to OGDH complex in rat heart and 
brain mitochondrial extracts very different spectra of peptides were detected (Figure 8b).  In 
the case of rat heart, peptides 2 and 3 were found with barely detectable amounts of 
peptides 7 and 9 whereas in rat brain peptides 2 and 3 were found together with significant 
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amounts of peptides 6,7,9 and 10.  These results are compatible with the conclusions of the 
RNA-seq studies; namely, that in the heart the OGDH complex contains predominantly 
archetype E1 whereas in the brain there is also comparable expression of the calcium-
insensitive splice variants.  The considerably greater amounts of peptide 9 compared to 
peptide 7 indicates that splice variant LS1/Insert may be expressed in greater amounts than 
Insert in rat brain.  It should be noted that peptide 6 was detected in rat brain indicating 
some expression also of LS1.  (The reason this peptide is detected in rat brain but not in 
expressed human LS1 is likely to be because an aspartate in the human sequence is changed 
to histidine thus lowering the mass/charge ratio.) 
 The preparation of rat brain and heart mitochondrial extracts used in these studies 
had involved sedimentation of OGDH complex at 250,000g for 60 min.  Thus it can be 
concluded that the Ca2+ -insensitive splice variants are part of a high molecular weight 
complex, most likely OGDH complex.  It is noteworthy that two other proteins that have a 
high degree of sequence identity with OGDH E1 were also found in these preparations.  
These are OGDHL (OGDH-like) and DHTDK1 (dehydrogenase E1 and transketolase domain 
containing 1) which may also replace E1 in OGDH complexes [19-21] but the identity of their 
substrates has not been established.   The amounts of both OGDHL and DHTDK1 in rat brain 
expressed as PSM as % archetype OGDH E1 PSM were 51±1.8 and 20±1.5% respectively 
which was considerably greater than the corresponding values for rat heart of 14±1.8 and 
3±0.2% respectively (results are mean±S.E.M. for observations on four different 
preparations in each case).  These observations are in general agreement of those of Bunik 
and colleagues [19]. 
 
OGDH complexes from rat heart and brain mitochondria have different Ca2+-sensitivity. 
The RNA-seq and proteomic studies above both indicated that the OGDH complex in 
mammalian heart mitochondria contained predominately the Ca2+-sensitive archetype E1 
whereas that in mammalian brain mitochondria contained comparable amounts of 
archetype E1 and a mix of the Ca2+-insensitive splice variants.  It follows that OGDH complex 
from mitochondria from the two tissues should exhibit differences in sensitivity to Ca2+.  In 
particular, the activity of the brain complex measured in the presence of Ca2+ and at a low 
concentration of 2-oxoglutarate should be less than that of the heart complex when 
expressed as a % of the Vmax (measured at 2 mM 2-oxoglutarate and 326 µM Ca2+).  
 Comparisons of the activity of OGDH complex in extracts of rat and brain 
mitochondria showed that this was the case.  The data in Figure 9a are from studies on 
single extracts of rat heart and brain mitochondria in which OGDH complex was assayed at 
50 µM 2-oxoglutarate and a range of concentrations of Ca2+.  Increasing [Ca2+] from <0.01 to 
326 µM increased activity by 63% of Vmax in the rat heart preparation but only 38% in that 
from rat brain.  If the assumption is made that the heart complex only contains the Ca2+ - 
sensitive archetype E1, then the proportion of Ca2+ -insensitive forms in the brain can be 
estimated as (1-(38/63)) = 0.40.  This is in close agreement with the RNA-seq and proteomic 
data (Figures 6 and 8).  Figure 9b summarises data on four separate preparations of rat 
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brain and heart mitochondria.  The activities at 50 µM 2-oxoglutarate and at 0.25, 0.59 and 
326 µM Ca2+ are all significantly lower in the brain whereas the activity at <0.01 µM is not 
significantly different.  The estimate of the proportion of Ca2+ - insensitive forms from these 
data is (1-(41/63)) = 0.35 confirming the conclusion from Figure 9a.   Our studies also 
showed that there may be a small increase in the K0.5 for Ca2+ for the OGDH complex from 
the brain compared with the heart.  The values for the brain OGDH complex calculated from 
the data of Figure 9a and Figure 9b were 0.74 µM and 0.57 µM respectively.  The 
corresponding values for OGDH complex from the heart were both 0.36 µM.   
The greater proportion of Ca2+-insensitive splice variants in rat brain OGDH complex 
would be expected to effect the sensitivity to 2-oxoglutarate in the presence of Ca2+ 
compared with that of rat heart.  This was observed (Figure 10).  All the data fitted simple 
Michaelis kinetics reasonably well (solid lines).  The Km ± S.E.M. in the presence of 326 µM 
Ca2+ was increased from 0.067 ± 0.005 in the heart to 0.183 ± 0.019 mM in the brain 
preparation.  In contrast, there was no appreciable difference at <0.01 µM Ca2+ where the 
values were 1.29±0.19 mM for brain and 1.17±0.12 mM for heart.  The data for rat brain in 
the presence of Ca2+ were also fitted to a 2 Km model (dashed line) assuming a mix of Ca2+ -
insensitive (Km = 1.17 mM) and Ca2+ -sensitive (Km = 0.067 mM) forms.  The calculated 
proportion of the Ca2+ -insensitive form from this approach was 45%, in agreement with 
comparable estimates using the Ca2+ -sensitivity data of Figure 9.  However, the fit was not 
as good as the single Km model and this is discussed further below. 
 
DISCUSSION  
Regulation of the splice variants of OGDH E1 
Our previous study showed that site 1 is an essential part of the Ca2+-binding site on 
archetype OGDH E1 [8].  In particular, replacement of D114ADLD with A114AALA resulted in 
essentially complete loss of Ca2+-activation of archetype OGDH E1.  We therefore predicted 
that the splice variant LS1, which lacks site 1, would be Ca2+-insensitive.  This prediction has 
been confirmed in the present study.  Perhaps a little surprisingly, the splice variant Insert 
which has the insertion of 15 amino acids just downstream of site 1 was also found to 
exhibit much attenuated Ca2+ activation.  It seems likely that this insertion causes a major 
disruption of Ca2+-binding in some way.  The binding of Ca2+ to proteins invariably involves 
six or seven co-ordinations [22] and thus Ca2+-binding to OGDH E1 is very likely to involve 
co-ordinations beyond site 1 which may be disrupted by the insertion of 15 amino acids.  
However, it should be noted that it is, at least theoretically, possible that Ca2+-binding is still 
intact but its influence on the activity of the enzyme is greatly decreased.  At high 
concentrations of Ca2+ (0.33 and 1.0 mM), we found some evidence of activation with all 
three splice variants with the greatest activation with splice variant Insert and the least with 
variant LS1/Insert.  However, the activation was markedly less with all three splice variants 
than that observed with archetype E1.  In any case, the small differences between the 
variants are probably of little physiological importance since over the range of 
intramitochondrial concentrations of Ca2+ that usually occur physiologically (0.1 – 50 µM; 
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[23-26] or up to 500 µM in the case of caffeine-stimulated chromaffin cells [27]) all three 
splice variants will be essentially Ca2+-insensitive, with the possible exception of the insert 
variant (Figure 3) which represents the most minor form in most tissues (Figure 6b). 
Whether these differences assume more importance in pathophysiological circumstances 
(ischaemia, hypoxia etc), where mitochondrial Ca2+ levels may exceed this range [28], is 
unclear.  
 All three splice variants still exhibit inhibition both by NADH and by increasing 
ATP/ADP ratios that is similar in extent to archetype E1 but the Ki and K0.5 values are 
somewhat higher.  In summary, the major loss of Ca2+-sensitivity in the variants is 
accompanied by modest decreases in sensitivity to inhibition by both NADH and elevated 
ATP/ADP ratios.  
Differential expression of splice variants in various mammalian tissues 
Our RNA-seq studies showed substantial differences in relative expression of the Ca2+- 
activated archetype OGDH E1 and the Ca2+-insensitive splice variants (at the mRNA level) 
across a wide range of mouse tissues.  In heart and skeletal muscle, archetype E1 accounted 
for some 95% of the total expression whereas its expression in brain, spleen and pancreatic 
islets was only about 50% with the expression of the three variants taken together making 
up the other 50%.  In embryonic stem cells, liver, kidney and lung the expression of the 
three variants in total ranged from 15 – 33% of that of archetype OGDH E1.  In all cases the 
splice variant LS1 appeared to be the predominant variant expressed. 
The proteomic approach we used to explore expression at the protein level in rat 
heart and brain confirmed the marked difference in expression of archetype and its splice 
variants seen in the RNA-seq studies.  In particular, there was little evidence of any 
expression of the Ca2+-insensitive splice variants in heart OGDH complex whereas in the 
complex from brain the total amount of the insensitive variants appeared to be comparable 
with that of archetype OGDH E1.  However, as explained under Results, it is more difficult to 
get an accurate measure of the LS1 variant than the other variants because a large unique 
peptide may be poorly detected. 
 We have also shown that there are clear differences in the Ca2+-sensitivity of the 
OGDH complex from rat brain and heart.  Our observations are compatible with the 
presence of only the Ca2+- activated archetype OGDH E1 with little or no Ca2+-insensitive 
splice variants in the heart while in the brain the Ca2+- insensitive splice variants are present 
in equivalent activity to that of archetype.  In heart and brain tissue, the agreement 
between the RNA-seq, proteomic and activity studies is both impressive and reassuring.   It 
should be noted that we found, in agreement with Bunik et al. [19], that the brain OGDH 
complex contains considerably more OGDHL and DHTDK1 than the heart complex and so 
the possibility arises that this difference may contribute to the observed differences in Ca2+-
sensitivity.  However, we are unaware of any evidence that 2-oxoglutarate is actually a 
substrate for either OGDHL or DHTDK1.  We have expressed human OGDHL using the same 
approach that we successfully used for the expression of archetype OGDH E1 but the 
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preparation was completely inactive with 2-oxoglutarate as substrate (Denton & Armstrong, 
unpublished work). 
     An interesting area for future study in the brain and other tissues will be the extent 
to which archetype OGDH E1 and the splice variants are present in distinct OGDH 
complexes, perhaps in different cells, or are present in the same complex as homo- or mixed 
E1 dimers.  Our studies have not addressed this aspect in any direct way but the relatively 
poor fit of the 2-oxoglutarate sensitivity of the OGDH complex from rat brain to a simple 
two Km model might reflect the presence of the homo- or mixed E1 dimers on the same 
OGDH complexes. Useful future direct approaches may include immunocytochemical 
techniques coupled to super-resolution optical imaging [29] or electron microscopy. 
Evolution of the calcium insensitive splice variants 
Based on direct studies of Ca2+- sensitivity, our previous studies have shown that the OGDH 
complexes from human, rat, mouse, pig, frog, pigeon and zebra-fish are activated by Ca2+ 
whereas those from drosophila, locust, C. elegans, yeast and E. coli are not [4,8,30,31].  
These observations suggest that Ca2+-sensitivity may be restricted to vertebrates. This view 
is strengthened and refined by the presence of DADLD within site 1 of OGDH E1 from most 
chordate (including vertebrate) sources but not from non-chordate sources.  An interesting 
exception is the elephant shark (Callorhinchus milii) which has AADLD and hence would be 
expected to exhibit greatly attenuated activation as found when DADLD within human 
OGDH E1 is mutated to this sequence [8]. 
Using published annotations of sequenced genomes combined with Blast searches 
(Materials and Methods), we have further explored the evolution of exons capable of giving 
rise to the splice variants LS1 and Insert.  An evolutionary tree of protein sequences 
alongside the motifs around Site 1, and the corresponding sequence in LS1 for these 
illustrative species, are shown in Figure 11a and in more detail in Supplementary Table S2. 
The key changes are shown in an evolutionary tree of species in Figure 11b.  The first of 
these (A) is a duplication of an exon (equivalent to exon 4) to give rise to exon 3 (LS1). The 
alternative splicing of these two exons is observed in both sea urchins and chordates and so 
presumably arose before the divergence of echinoderms and chordates. Next (B) the 
evolution of the DADLD motif occurred early in chordate evolution.  Since the DADLD motif 
appears to be essential for Ca2+ sensitivity, this suggests that the development of Ca2+-
sensitive OGDH was preceded by the development of an alternatively-spliced variant which 
retained the ancestral Ca2+ insensitivity.  The gain of the Insert exon (C) occurred in a 
common ancestor of cartilaginous and bony fish, giving rise to two further Ca2+ insensitive 
splice variants in this lineage. It might therefore be speculated that the ability to express a 
Ca2+-insensitive variant is essential, presumably in a tissue-specific or developmentally-
regulated manner.  Nonetheless, the reason for the existence of three nominally Ca2+ 
insensitive variants, which differ in their response to very high (usually pathological) 
concentrations of the ion, remains unclear (see above).  Of note, NAD+-isocitrate 
dehydrogenase also shows a broad range of Ca2+ sensitivities depending on ATP/ADP and 
NADH/NAD+ ratios [6] suggesting that a retained ability of the insert variant of OGDH (Figure 
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3) to respond to very high (> 100 µM) Ca2+ levels might be of relevance under some 
circumstances.  
The duplication of the Ogdh gene giving rise to Ogdhl occurred before the 
divergence of cartilaginous fish, and presumably before the gain of the Insert exon (C) since 
this is not found in any Oghdl genes. In the ray-finned fish, a further gene duplication (D) 
gave rise to two OGDH E1 genes (Ogdha and Ogdhb).  Subsequently, the S1 exon was lost in 
Ogdha (E) in a subgroup, presumably rendering it Ca2+ insensitive.  This may indicate that 
the balance in the expression of Ca2+-sensitive versus insensitive OGDH isoforms is regulated 
to a greater extent in these fish at the transcriptional level rather than through alternative 
splicing. 
Role of calcium insensitive splice variants in mammalian tissues 
The current studies have shown at the RNA and protein level, as well as by activity studies, 
that the Ca2+-sensitive archetype OGDH E1 is the predominant form (over 95%) of E1 in the 
heart and in skeletal muscle whereas in the brain about half is a calcium insensitive variant.  
The amounts of calcium insensitive variants in some other tissues such as liver and kidney 
based on RNA levels would appear to be about 25% of the archetypal form.   These tissue 
specific variations and likely roles of the archetype and variant forms are summarised in 
Figure 12. 
 We have previously argued that in vertebrates the Ca2+- sensitivity of the OGDH 
complex coupled with that of two other intramitochondrial enzymes (pyruvate 
dehydrogenase phosphatase and NAD-isocitrate dehydrogenase, NAD-ICDH) is an important 
mechanism for matching ATP supply and demand [4,32-34]. The results of the present study 
fully support this view for the heart where the principal role of the OGDH complex is to 
regulate the citrate cycle.  Supporting this are recent studies [35,36] involving the 
inactivation of the mitochondrial Ca2+-uniporter (MCU) [37,38] selectively in the heart.  The 
latter studies demonstrated a role for mitochondrial Ca2+ uptake in the acceleration of heart 
rate during fight or flight [35], with inactivation of the transporter through the over-
expression of a dominant-negative variant also leading to a suite of compensatory changes 
including an elevation in cytoplasmic Ca2+ levels [36].  Correspondingly, mice globally 
deleted for the MCU gene display an impaired ability to perform strenuous work and 
changes in the phosphorylation state of the pyruvate dehydrogenase complex in skeletal 
muscle [39].  
In non-muscle tissues, the role of the OGDH complex in metabolism has more 
dimensions including an important role in glutamine and glutamate metabolism.  It seems 
most likely that the Ca2+- insensitive splice variants facilitate this multifaceted role by 
modifying (attenuating) large Ca2+-dependent changes in OGDH complex activity during 
cellular stimulation.  In the brain, glutamate serves as  an essential neurotransmitter [40] 
whose intracellular levels may need to be maintained during action potential firing and Ca2+-
dependent exocytosis.  Ca2+ activation of OGDH, which would be expected to increase 
glutamate catabolism after conversion to 2-oxoglutarate by glutamate dehydrogenase, may 
therefore need to be minimised under these conditions.  We note, however, that our 
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measurements in brain are likely to be affected by the presence of glial cells [41] and future 
studies may be required to determine the distribution of OGDH variants in these versus 
neurons.  
Glutamate also has important roles in the pancreatic islet β cell both as an 
extracellular [42] and intracellular [43-45] signal, and is implicated in the control of insulin 
secretion by glucose and by incretin hormones.  Whilst levels of the splice variants in islets 
may not precisely reflect those in β cells (which comprise 60-70% of rodent islets) [46], it 
seems possible that the lower levels of archetype OGDH E1 in these cells may, in common 
with neurons, reflect a requirement to avoid large Ca2+-dependent changes in glutamate 
catabolism during stimulation with secretagogues. 
We have also considered the possibility that changes in the ratio of splice variants 
may occur in cancer cells given the dependence upon glutamine metabolism apparent in 
tumours [47,48] . Whilst we did not perform a comprehensive screen across multiple cancer 
types our analysis (not shown) of RNASeq data from transformed versus untransformed 
mouse embryonic fibroblasts [49] did not show any significant differences in the expression 
of splice variants of OGDH E1.  
 In summary, the existence of Ca2+ sensitive and insensitive variants of OGDH 
appears to be a relatively early evolutionary adaptation, which allows the tissue-specific 
regulation of the enzyme in mammals and presumably in other chordates.    
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Figure 1   Alignment of human archetype and splice variants of OGDH E1 and arrangement 
of exons. 
(a)  Sequence of archetypal is from Leu94 – Leu148 (using sequence numbering after cleavage 
of mitochondrial propeptide).  Sequence corresponding to the archetypal site 1 exon (exon 
4) shown in green with site 1 in bold type.  Sequences corresponding to loss of site 1 exon 
(exon 3) is shown in blue and Insert exon (exon 5) in red.  Site 2 sequence is underlined and 
is present in all the variants.  (b)   Arrangement of exons in vertebrate OGDH genes. 
Figure 2   Survey of effects of adenine nucleotides, NADH and Ca2+on the activity of human 
OGDH E1 splice variants. 
(a) Archetype.   (b) LS1.  (c)  Insert.  (d)  LS1/Insert.   All activities were measured at 50 µM 2-
oxoglutarate in the presence and absence of adenine nucleotides, NADH and Ca2+ as 
indicated and are expressed as % Vmax.  Values are mean ± S.E.M. for four determinations.  
Further details of the observations are given in Supplementary Table S1. 
 
Figure 3   Effects of Ca2+ on the activity of human OGDH E1 splice variants. 
 
All activities were measured at 50 µM 2-oxoglutarate in the presence of 0.2 mM NADH (but 
in the absence of adenine nucleotides) at <0.01, 326 and 996 µM Ca2+ and are expressed as 
% Vmax .  Values are mean ± S.E.M for 4-6 observations.  *P<0.05, **P<0.01 (Student’s t test) 
compared to <0.01 µM Ca2+.  Note, under the same conditions used in the present study the 
K0.5 for Ca2+ activation of archetype OGDH E1 was 7.81±0.87 µM [8]. 
 
Figure 4   Inhibition of human OGDH E1 splice variants by NADH and ATP/ADP. 
 (a)  Effects of increasing concentrations of NADH in the presence of 50 µM 2-oxoglutarate, 
<0.01 µM Ca2+ and the absence of adenine nucleotides.  Points are the mean of 3-5 
observations.  Dated fitted to :-  v = v0 – ((v0-vni).[NADH]/([NADH]+Ki)) where V0 is the rate in 
the absence of NADH, vni is the non-inhibitable rate and Ki is the concentration of NADH 
giving half-maximal effects.  (b)  Effects of increasing ratios of ATP to ADP (with the ATP plus 
ADP concentration constant at 1.5 mM) in the presence of 50µM 2-oxoglutarate, <0.01 µM 
Ca2+ and the absence of NADH.  Points are the mean of 2-6 observations.  Data fitted to 
same equation as in (a) but with ATP/ADP ratio replacing [NADH].  (c) Values of Ki for NADH 
and the ratio of ATP/ADP giving 50% inhibition calculated from the data plotted in parts (a) 
and (b) and given as parameter mean ± S.E.M. (based on 7-11 mean observations). 
Figure 5   Effects of 2-oxoglutarate concentration in the presence and absence of NADH 
(0.2 mM) and [Ca2+] <0.01 µM on the activity of human OGDH E1 splice variants. 
(a)  Comparison of archetype with LS1 splice variant. Each point is the mean of three 
observations.  Data fitted to:-  v = Vmax . [OG]/([OG] + Km).     (b)  Values of Km calculated 
from the data plotted in (a) and given as parameter mean ± S.E.M. (based on 6 mean 
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observations).  Also included are values for variants Insert and LS1/Insert calculated from 
data obtained under the same conditions as in (a) and again given as mean±S.E.M based on 
6 mean observations. 
Figure 6  Expression patterns of archetype and splice variants determined from RNA-Seq 
data. 
(a) Expression levels of mRNA encoding archetype and the three splice variants of OGDH E1 
were measured across a range of adult mouse tissues and embryonic stem cells (ESC) from 
publicly available RNA-Seq data using the Sailfish tool.  Data presented as mean ± S.E.M. 
(n=2-3).  (b) These data are also presented to show the proportion of the variants expressed 
in each tissue. (c) Exon-level expression analysis of archetype and splice variants in mouse 
cortex and heart using DEXSeq. The exons encoding LS1, archetype and Insert are 
highlighted and expanded in the bottom part.  Due to differences in the LS1 boundaries 
present in the reference annotation, this exon was split into two counting bins.  However, 
the predicted exon usage for both bins is almost identical in agreement with a single  LS1 
exon. (n=3) * Significantly different exon usage with false discovery rate <10-6. 
Figure 7 Trypsin derived peptides from archetype and splice variants of human OGDH E1  
Tryptic peptides from Leu84 to Arg164 for archetype OGDH E1 together with corresponding 
peptides for the three splice variants.  Peptides have been assigned a letter or number and 
these are shown under the peptides.  Peptides a and b are present in all four forms of OGDH 
E1.  Underlined peptides are unique to a single form.  Peptides from the four forms in rat 
and mouse are identical to those from human except *asp is replaced by his and †ser is 
replaced by pro. 
Figure 8  Proteomic analysis of tryptic peptides from (a) expressed archetype and splice 
variants of human OGDH E1 and (b) OGDH E1 separated from rat brain and heart 
mitochondria.     
Results are shown as peptide spectral matches (PSM) for the indicated peptide or the mean 
of peptides a and b expressed as a % of the total E1 protein PSM and are mean±S.E.M. of 
three or four observations. Values of total E1 protein PSM were archetype 3571±552 (4), 
LS1 3719±552 (3), Insert 3782±1961 (3), LS1/Insert 3407±156 (3), rat brain OGDH E1 
620±126 (4) and rat heart OGDH E1 1086±126 (4).   All observations were obtained using an 
Orbitrap Fusion Tribrid mass spectrometer.  The number of PSM is a measure of the amount 
of a peptide.  
Figure 9   Comparison of the effects of Ca2+ on the activity of OGDH complex in extracts of 
rat heart and brain mitochondria. 
Activity of the OGDH complex was assayed in the presence of 50µM 2-oxoglutarate (in the 
absence of added adenine nucleotides and NADH) and expressed as % Vmax (taken as the 
activity in the presence of 2mM oxoglutarate and 0.33mM Ca2+). (a) Observations on single 
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preparations of mitochondrial extracts using 11-12 different Ca2+ concentrations; data fitted 
to:-  v=Vmax.[Ca2+]/([Ca2+] + K0.5).  (b)  Mean results with four preparations each of rat heart 
and brain mitochondria measured at four concentrations of Ca2+.  
Figure 10   Effects of 2-oxoglutarate concentration on the activity of OGDH complex from 
rat brain and heart mitochondria.  
Activity of the OGDH complex was assayed in the presence of <0.01 or 326 µM Ca2+ (without 
added adenine nucleotides or NADH) and expressed as % Vmax.  Data points are the means 
of 2-4 observations on two separate preparations of mitochondria from each tissue.  Data 
fitted to :-  v = Vmax . [OG]/([OG] + Km) shown as solid lines.  Dashed line is data from brain at 
326 µM Ca2+ fitted assuming a mix of Ca2+-sensitive and Ca2+-insensitive forms with Km for 2-
oxoglutarate of 0.067 and 1.17 mM respectively;  the calculated proportion of the Ca2+ - 
insensitive form is 45±7%.   
Figure 11.  Phylogenetic development of OGDH E1 and OGDHL 
a  Evolutionary tree of OGDH protein sequences. Within each species, variants have been 
collapsed into a single node for clarity. An alignment of the S1, LS1 and insert motifs is 
provided. Ogdhl genes have similarly been collapsed. Mammals are highlighted in pink and 
ray-finned fish in blue. b  Evolutionary tree of species highlighting the major changes to the 
OGDH and OGDHL genes. The underlying tree was constructed using data from ENSEMBL as 
described under Materials and Methods.   
Figure. 12. Scheme indicating the likely roles of tissue-specific expression of Ca2+-sensitive 
archetype OGDH E1 (blue) and Ca2+-insensitive splice variants (LS1, insert, LS1-insert; 
green) in representative mammalian tissues.   
Approximate relative abundances and predicted fluxes of each are represented by the size 
of the circles and thicknesses of the arrows, respectively. Citrate cycle flux towards 
increased ATP synthesis (shown for heart, skeletal muscle) is implied for the other indicated 




Table S1  Survey of effects of adenine nucleotides, NADH and Ca2+on the activity of human 
OGDH E1 splice variants. 
 
These data were used to prepare Figure 2 of the main text. 
 
Table S2  Sequences expressed by LS1, site 1 (archetype) and Insert exons in selected 
vertebrates.   Data was obtained by use of BLASTp and tBlastn together with sequences of 
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human archetype E1 and its splice variants in conjunction with species genomic DNA 
sequence information.  The sequence of site 1 is shown in bold. 
 
